The survival analysis in the current study revealed that HER2 status (null, ultra-low or low expression) had no effect on DFS in HER2-negative BC patients (HER2-null vs HER2 ultra-low, P = 0.105; HER2 ultra-low vs HER2-low, P = 0.507, log–rank). Here, ERBB2 is linked to breast cancer.